GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunogen Inc (FRA:IMU) » Definitions » Loans Receivable

Immunogen (FRA:IMU) Loans Receivable : €0.0 Mil (As of Sep. 2023)


View and export this data going back to . Start your Free Trial

What is Immunogen Loans Receivable?

Immunogen's Loans Receivable for the quarter that ended in Sep. 2023 was €0.0 Mil.


Immunogen Loans Receivable Historical Data

The historical data trend for Immunogen's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunogen Loans Receivable Chart

Immunogen Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Immunogen Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Immunogen Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Immunogen Loans Receivable Related Terms

Thank you for viewing the detailed overview of Immunogen's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Immunogen (FRA:IMU) Business Description

Traded in Other Exchanges
Address
830 Winter Street, Waltham, MA, USA, 02451
Immunogen Inc is a clinical-stage biotechnology company from the United States. Its focus is antibody-drug conjugate, or ADC, technology, which uses an antibody that fixes on a target (its antigen) found on tumor cells to deliver a specific cancer-killing agent.

Immunogen (FRA:IMU) Headlines

No Headlines